<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on 23/11/2026 at 5:39 AM by All in One SEO v5.0.5 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://healthcareinsights.vn/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>HEALTHCARE INSIGHTS</title>
		<link><![CDATA[https://healthcareinsights.vn]]></link>
		<description><![CDATA[HEALTHCARE INSIGHTS]]></description>
		<lastBuildDate><![CDATA[Fri, 20 Nov 2026 02:46:17 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://healthcareinsights.vn/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://healthcareinsights.vn/nosebleeds-head-back-or-head-forward-correcting-a-common-first-aid-mistake-2/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/nosebleeds-head-back-or-head-forward-correcting-a-common-first-aid-mistake-2/]]></link>
			<title>Seizures: Should You Put Something In The Mouth? Correcting A Dangerous First Aid Habit</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 02:46:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/are-you-overweight-without-knowing-it-understanding-bmi-waist-circumference-and-visceral-fat-2/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/are-you-overweight-without-knowing-it-understanding-bmi-waist-circumference-and-visceral-fat-2/]]></link>
			<title>Stress, sleep loss and body weight: An overlooked connection in office life</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 02:45:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/from-experiments-to-business-results-why-ai-needs-workflow-redesign/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/from-experiments-to-business-results-why-ai-needs-workflow-redesign/]]></link>
			<title>From experiments to business results: Why AI needs workflow redesign</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:47:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/when-teams-stop-believing-their-effort-matters-what-leaders-can-do/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/when-teams-stop-believing-their-effort-matters-what-leaders-can-do/]]></link>
			<title>When teams stop believing their effort matters: what leaders can do</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:45:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/sanofis-infilbray-becomes-first-fda-approved-treatment-for-neurological-gaucher-type-3-can-blood-brain-barrier-penetration-create-a-new-competitive-advantage-in-rare-disease-therapies/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/sanofis-infilbray-becomes-first-fda-approved-treatment-for-neurological-gaucher-type-3-can-blood-brain-barrier-penetration-create-a-new-competitive-advantage-in-rare-disease-therapies/]]></link>
			<title>SANOFI&#8217;S INFILBRAY BECOMES FIRST FDA-APPROVED TREATMENT FOR NEUROLOGICAL GAUCHER TYPE 3: CAN BLOOD–BRAIN BARRIER PENETRATION CREATE A NEW COMPETITIVE ADVANTAGE IN RARE DISEASE THERAPIES</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:11:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/ellipses-pharma-eyes-500-million-london-valuation-can-the-uk-capital-market-reclaim-its-appeal-to-high-growth-oncology-biotech-companies/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/ellipses-pharma-eyes-500-million-london-valuation-can-the-uk-capital-market-reclaim-its-appeal-to-high-growth-oncology-biotech-companies/]]></link>
			<title>ELLIPSES PHARMA EYES £500 MILLION LONDON VALUATION: CAN THE UK CAPITAL MARKET RECLAIM ITS APPEAL TO HIGH-GROWTH ONCOLOGY BIOTECH COMPANIES</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:06:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/pfizer-enters-2-6-billion-in-vivo-car-t-deal-with-starna-can-direct-immune-cell-engineering-disrupt-the-cost-structure-of-cell-therapy/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/pfizer-enters-2-6-billion-in-vivo-car-t-deal-with-starna-can-direct-immune-cell-engineering-disrupt-the-cost-structure-of-cell-therapy/]]></link>
			<title>PFIZER ENTERS $2.6 BILLION IN VIVO CAR-T DEAL WITH STARNA: CAN DIRECT IMMUNE CELL ENGINEERING DISRUPT THE COST STRUCTURE OF CELL THERAPY</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:01:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/can-tho-inaugurates-vnd-950-billion-orthopedic-hospital-after-nearly-a-decade-can-300-new-beds-transform-specialized-surgical-care-in-the-mekong-delta/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/can-tho-inaugurates-vnd-950-billion-orthopedic-hospital-after-nearly-a-decade-can-300-new-beds-transform-specialized-surgical-care-in-the-mekong-delta/]]></link>
			<title>CAN THO INAUGURATES VND 950 BILLION ORTHOPEDIC HOSPITAL AFTER NEARLY A DECADE: CAN 300 NEW BEDS TRANSFORM SPECIALIZED SURGICAL CARE IN THE MEKONG DELTA?</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 06:57:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/vnvc-and-msd-plan-vaccine-manufacturing-partnership-in-vietnam-with-vnd-3-trillion-facility-can-core-technology-transfer-position-vietnam-in-the-global-vaccine-value-chain/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/vnvc-and-msd-plan-vaccine-manufacturing-partnership-in-vietnam-with-vnd-3-trillion-facility-can-core-technology-transfer-position-vietnam-in-the-global-vaccine-value-chain/]]></link>
			<title>VNVC AND MSD PLAN VACCINE MANUFACTURING PARTNERSHIP IN VIETNAM WITH VND 3 TRILLION FACILITY: CAN CORE TECHNOLOGY TRANSFER POSITION VIETNAM IN THE GLOBAL VACCINE VALUE CHAIN?</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 06:45:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/biogens-anti-tau-alzheimers-drug-slows-clinical-decline-by-38-at-two-years-could-rna-based-therapies-open-a-new-frontier-beyond-amyloid/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/biogens-anti-tau-alzheimers-drug-slows-clinical-decline-by-38-at-two-years-could-rna-based-therapies-open-a-new-frontier-beyond-amyloid/]]></link>
			<title>BIOGEN&#8217;S ANTI-TAU ALZHEIMER&#8217;S DRUG SLOWS CLINICAL DECLINE BY 38% AT TWO YEARS: COULD RNA-BASED THERAPIES OPEN A NEW FRONTIER BEYOND AMYLOID?</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 06:08:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/sepalna-wins-eu-approval-with-38-7-month-progression-free-survival-can-benefits-beyond-brca-mutations-reshape-competition-in-ovarian-cancer-maintenance-therapy/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/sepalna-wins-eu-approval-with-38-7-month-progression-free-survival-can-benefits-beyond-brca-mutations-reshape-competition-in-ovarian-cancer-maintenance-therapy/]]></link>
			<title>SEPALNA WINS EU APPROVAL WITH 38.7-MONTH PROGRESSION-FREE SURVIVAL: CAN BENEFITS BEYOND BRCA MUTATIONS RESHAPE COMPETITION IN OVARIAN CANCER MAINTENANCE THERAPY?</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 06:04:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/gsks-nelkarmi-wins-accelerated-fda-approval-with-49-tumor-response-rate-can-the-10-6-billion-nuvalent-acquisition-rebuild-gsks-competitive-position-in-oncology/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/gsks-nelkarmi-wins-accelerated-fda-approval-with-49-tumor-response-rate-can-the-10-6-billion-nuvalent-acquisition-rebuild-gsks-competitive-position-in-oncology/]]></link>
			<title>GSK&#8217;S NELKARMI WINS ACCELERATED FDA APPROVAL WITH 49% TUMOR RESPONSE RATE: CAN THE $10.6 BILLION NUVALENT ACQUISITION REBUILD GSK&#8217;S COMPETITIVE POSITION IN ONCOLOGY?</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 05:58:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/gilead-signs-royalty-free-ebola-drug-licensing-deals-covering-127-countries-can-early-technology-transfer-reshape-global-access-to-outbreak-therapies/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/gilead-signs-royalty-free-ebola-drug-licensing-deals-covering-127-countries-can-early-technology-transfer-reshape-global-access-to-outbreak-therapies/]]></link>
			<title>GILEAD SIGNS ROYALTY-FREE EBOLA DRUG LICENSING DEALS COVERING 127 COUNTRIES: CAN EARLY TECHNOLOGY TRANSFER RESHAPE GLOBAL ACCESS TO OUTBREAK THERAPIES?</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 05:53:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/merck-halts-entire-nemtabrutinib-blood-cancer-program-after-benefit-risk-review-is-the-btk-inhibitor-race-entering-a-more-demanding-phase-of-clinical-competition/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/merck-halts-entire-nemtabrutinib-blood-cancer-program-after-benefit-risk-review-is-the-btk-inhibitor-race-entering-a-more-demanding-phase-of-clinical-competition/]]></link>
			<title>MERCK HALTS ENTIRE NEMTABRUTINIB BLOOD CANCER PROGRAM AFTER BENEFIT–RISK REVIEW: IS THE BTK INHIBITOR RACE ENTERING A MORE DEMANDING PHASE OF CLINICAL COMPETITION?</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 04:43:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/can-thos-vnd-2-trillion-oncology-hospital-reaches-90-construction-completion-can-infrastructure-investment-translate-into-greater-cancer-treatment-capacity-in-the-mekong-delta/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/can-thos-vnd-2-trillion-oncology-hospital-reaches-90-construction-completion-can-infrastructure-investment-translate-into-greater-cancer-treatment-capacity-in-the-mekong-delta/]]></link>
			<title>CAN THO&#8217;S VND 2 TRILLION ONCOLOGY HOSPITAL REACHES 90% CONSTRUCTION COMPLETION: CAN INFRASTRUCTURE INVESTMENT TRANSLATE INTO GREATER CANCER TREATMENT CAPACITY IN THE MEKONG DELTA?</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 03:27:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/vinmec-targets-50-reduction-in-car-t-treatment-costs-to-vnd-1-5-billion-can-domestic-cell-therapy-manufacturing-transform-access-to-advanced-medicine-in-vietnam/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/vinmec-targets-50-reduction-in-car-t-treatment-costs-to-vnd-1-5-billion-can-domestic-cell-therapy-manufacturing-transform-access-to-advanced-medicine-in-vietnam/]]></link>
			<title>VINMEC TARGETS 50% REDUCTION IN CAR-T TREATMENT COSTS TO VND 1.5 BILLION: CAN DOMESTIC CELL THERAPY MANUFACTURING TRANSFORM ACCESS TO ADVANCED MEDICINE IN VIETNAM?</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 03:17:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/roches-gazyva-wins-first-fda-approval-for-rare-kidney-disease-with-36-1-complete-remission-rate-can-autoimmune-expansion-drive-growth-beyond-blood-cancer/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/roches-gazyva-wins-first-fda-approval-for-rare-kidney-disease-with-36-1-complete-remission-rate-can-autoimmune-expansion-drive-growth-beyond-blood-cancer/]]></link>
			<title>ROCHE&#8217;S GAZYVA WINS FIRST FDA APPROVAL FOR RARE KIDNEY DISEASE WITH 36.1% COMPLETE REMISSION RATE: CAN AUTOIMMUNE EXPANSION DRIVE GROWTH BEYOND BLOOD CANCER?</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 07:34:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/eli-lilly-signs-potential-5-9-billion-oncology-deal-with-stipple-bio-can-epitope-level-precision-redefine-competitive-advantage-in-targeted-cancer-therapies/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/eli-lilly-signs-potential-5-9-billion-oncology-deal-with-stipple-bio-can-epitope-level-precision-redefine-competitive-advantage-in-targeted-cancer-therapies/]]></link>
			<title>ELI LILLY SIGNS POTENTIAL $5.9 BILLION ONCOLOGY DEAL WITH STIPPLE BIO: CAN EPITOPE-LEVEL PRECISION REDEFINE COMPETITIVE ADVANTAGE IN TARGETED CANCER THERAPIES?</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 07:32:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/helus-pharma-achieves-50-9-depression-remission-in-phase-3-trial-could-safety-concerns-slow-the-commercialization-of-psychedelic-therapies/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/helus-pharma-achieves-50-9-depression-remission-in-phase-3-trial-could-safety-concerns-slow-the-commercialization-of-psychedelic-therapies/]]></link>
			<title>HELUS PHARMA ACHIEVES 50.9% DEPRESSION REMISSION IN PHASE 3 TRIAL: COULD SAFETY CONCERNS SLOW THE COMMERCIALIZATION OF PSYCHEDELIC THERAPIES?</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 07:16:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/loreal-settles-cancer-claims-amid-more-than-12700-hair-relaxer-lawsuits-is-product-safety-risk-becoming-a-strategic-threat-to-the-global-beauty-industry/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/loreal-settles-cancer-claims-amid-more-than-12700-hair-relaxer-lawsuits-is-product-safety-risk-becoming-a-strategic-threat-to-the-global-beauty-industry/]]></link>
			<title>L’ORÉAL SETTLES CANCER CLAIMS AMID MORE THAN 12,700 HAIR RELAXER LAWSUITS: IS PRODUCT SAFETY RISK BECOMING A STRATEGIC THREAT TO THE GLOBAL BEAUTY INDUSTRY?</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 07:11:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/us-loses-measles-elimination-status-after-26-years-is-declining-vaccination-coverage-exposing-structural-weaknesses-in-public-health-systems/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/us-loses-measles-elimination-status-after-26-years-is-declining-vaccination-coverage-exposing-structural-weaknesses-in-public-health-systems/]]></link>
			<title>US LOSES MEASLES ELIMINATION STATUS AFTER 26 YEARS: IS DECLINING VACCINATION COVERAGE EXPOSING STRUCTURAL WEAKNESSES IN PUBLIC HEALTH SYSTEMS?</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 07:07:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/lao-cai-opens-medical-skills-training-center-can-university-hospital-collaboration-address-healthcare-workforce-capability-gaps-in-vietnams-mountainous-regionslao-cai-opens-medical/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/lao-cai-opens-medical-skills-training-center-can-university-hospital-collaboration-address-healthcare-workforce-capability-gaps-in-vietnams-mountainous-regionslao-cai-opens-medical/]]></link>
			<title>LAO CAI OPENS MEDICAL SKILLS TRAINING CENTER: CAN UNIVERSITY–HOSPITAL COLLABORATION ADDRESS HEALTHCARE WORKFORCE CAPABILITY GAPS IN VIETNAM’S MOUNTAINOUS REGIONS?</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 04:10:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/vietnam-targets-1-billion-in-medical-tourism-revenue-by-2030-can-international-standardization-build-a-competitive-advantage-against-regional-healthcare-hubs/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/vietnam-targets-1-billion-in-medical-tourism-revenue-by-2030-can-international-standardization-build-a-competitive-advantage-against-regional-healthcare-hubs/]]></link>
			<title>VIETNAM TARGETS $1 BILLION IN MEDICAL TOURISM REVENUE BY 2030: CAN INTERNATIONAL STANDARDIZATION BUILD A COMPETITIVE ADVANTAGE AGAINST REGIONAL HEALTHCARE HUBS?</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 04:02:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/dien-bien-opens-vnd-541-5-billion-private-hospital-can-healthcare-investment-in-vietnams-mountainous-provinces-deliver-sustainable-growth/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/dien-bien-opens-vnd-541-5-billion-private-hospital-can-healthcare-investment-in-vietnams-mountainous-provinces-deliver-sustainable-growth/]]></link>
			<title>DIEN BIEN OPENS VND 541.5 BILLION PRIVATE HOSPITAL: CAN HEALTHCARE INVESTMENT IN VIETNAM’S MOUNTAINOUS PROVINCES DELIVER SUSTAINABLE GROWTH?</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 03:26:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/vidipha-governance-restructuring-ownership-shift-vietnam-pharma/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/vidipha-governance-restructuring-ownership-shift-vietnam-pharma/]]></link>
			<title>VIDIPHA GOVERNANCE RESTRUCTURING AFTER 34% OWNERSHIP SHIFT: A NEW GROWTH OPPORTUNITY FOR VIETNAM&#8217;S PHARMA INDUSTRY?</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 03:17:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/vietnam-tightens-hiv-data-privacy-controls-could-declining-patient-trust-undermine-the-effectiveness-of-hiv-prevention/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/vietnam-tightens-hiv-data-privacy-controls-could-declining-patient-trust-undermine-the-effectiveness-of-hiv-prevention/]]></link>
			<title>VIETNAM TIGHTENS HIV DATA PRIVACY CONTROLS: COULD DECLINING PATIENT TRUST UNDERMINE THE EFFECTIVENESS OF HIV PREVENTION?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 06:56:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/orphalan-expands-phase-3-wilson-disease-trial-into-china-can-once-daily-treatment-create-a-new-competitive-advantage-in-rare-disease-care/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/orphalan-expands-phase-3-wilson-disease-trial-into-china-can-once-daily-treatment-create-a-new-competitive-advantage-in-rare-disease-care/]]></link>
			<title>ORPHALAN EXPANDS PHASE 3 WILSON DISEASE TRIAL INTO CHINA: CAN ONCE-DAILY TREATMENT CREATE A NEW COMPETITIVE ADVANTAGE IN RARE DISEASE CARE?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 06:51:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/event/apaaaci-2026/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/event/apaaaci-2026/]]></link>
			<title>APAAACI 2026</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 05:08:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/event/vamim-2026/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/event/vamim-2026/]]></link>
			<title>VAMIM 2026</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 05:01:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/event/pharmapack/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/event/pharmapack/]]></link>
			<title>VIETNAM MEDI-PHARM 2026</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 04:52:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/fda-rejects-summits-ivonescimab-despite-48-lower-risk-of-disease-progression-could-the-survival-evidence-gap-slow-the-pd-1-x-vegf-race/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/fda-rejects-summits-ivonescimab-despite-48-lower-risk-of-disease-progression-could-the-survival-evidence-gap-slow-the-pd-1-x-vegf-race/]]></link>
			<title>FDA REJECTS SUMMIT&#8217;S IVONESCIMAB DESPITE 48% LOWER RISK OF DISEASE PROGRESSION: COULD THE SURVIVAL EVIDENCE GAP SLOW THE PD-1 × VEGF RACE?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 03:36:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/eli-lilly-reports-up-to-23-3-weight-loss-with-combination-therapy-can-stronger-efficacy-sustain-its-leadership-in-the-obesity-drug-market/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/eli-lilly-reports-up-to-23-3-weight-loss-with-combination-therapy-can-stronger-efficacy-sustain-its-leadership-in-the-obesity-drug-market/]]></link>
			<title>ELI LILLY REPORTS UP TO 23.3% WEIGHT LOSS WITH COMBINATION THERAPY: CAN STRONGER EFFICACY SUSTAIN ITS LEADERSHIP IN THE OBESITY DRUG MARKET?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 03:19:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/vietnam-accelerates-ai-adoption-in-ophthalmology-can-digital-diagnostics-close-eyecare-gaps-and-reduce-preventable-blindness/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/vietnam-accelerates-ai-adoption-in-ophthalmology-can-digital-diagnostics-close-eyecare-gaps-and-reduce-preventable-blindness/]]></link>
			<title>VIETNAM ACCELERATES AI ADOPTION IN OPHTHALMOLOGY: CAN DIGITAL DIAGNOSTICS CLOSE EYECARE GAPS AND REDUCE PREVENTABLE BLINDNESS?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 03:08:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/1000-ho-chi-minh-city-residents-receive-free-health-checkups-can-community-based-preventive-care-deliver-sustainable-value-for-vietnams-healthcare-system/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/1000-ho-chi-minh-city-residents-receive-free-health-checkups-can-community-based-preventive-care-deliver-sustainable-value-for-vietnams-healthcare-system/]]></link>
			<title>1,000 HO CHI MINH CITY RESIDENTS RECEIVE FREE HEALTH CHECKUPS: CAN COMMUNITY-BASED PREVENTIVE CARE DELIVER SUSTAINABLE VALUE FOR VIETNAM&#8217;S HEALTHCARE SYSTEM?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 03:03:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/ho-chi-minh-city-dermatology/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/ho-chi-minh-city-dermatology/]]></link>
			<title>HO CHI MINH CITY DERMATOLOGY ASSOCIATION EXPANDS ITS ADVISORY ROLE: CAN PROFESSIONAL STANDARDS RESHAPE VIETNAM&#8217;S MEDICAL AESTHETICS MARKET?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 02:58:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/dkshs-390-million-newbridge-deal-why-specialty-pharma-commercialization-is-becoming-a-strategic-asset-beyond-drug-distribution/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/dkshs-390-million-newbridge-deal-why-specialty-pharma-commercialization-is-becoming-a-strategic-asset-beyond-drug-distribution/]]></link>
			<title>BEYOND DRUG DISTRIBUTION: DKSH’S $390 MILLION BET ON SPECIALTY PHARMA COMMERCIALIZATION</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 13:56:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/newletter/vol-51_nov-09-2026_newsletter/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/newletter/vol-51_nov-09-2026_newsletter/]]></link>
			<title>Vol 51_Nov.09.2026_Newsletter</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 10:45:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/vietnam-targets-at-least-20-fewer-hospital-referrals-through-technical-transfer-reform-can-outcome-based-capacity-building-reduce-pressure-on-tertiary-hospitals/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/vietnam-targets-at-least-20-fewer-hospital-referrals-through-technical-transfer-reform-can-outcome-based-capacity-building-reduce-pressure-on-tertiary-hospitals/]]></link>
			<title>VIETNAM TARGETS AT LEAST 20% FEWER HOSPITAL REFERRALS THROUGH TECHNICAL TRANSFER REFORM: CAN OUTCOME-BASED CAPACITY BUILDING REDUCE PRESSURE ON TERTIARY HOSPITALS?</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 10:07:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/bubble-tea-birthday-cake-and-business-dinners-the-hidden-calorie-traps-of-office-life/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/bubble-tea-birthday-cake-and-business-dinners-the-hidden-calorie-traps-of-office-life/]]></link>
			<title>Bubble tea, birthday cake and business dinners: The hidden calorie traps of office life</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 03:24:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/choking-back-blows-or-abdominal-thrusts-getting-the-first-few-minutes-right/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/choking-back-blows-or-abdominal-thrusts-getting-the-first-few-minutes-right/]]></link>
			<title>Choking: Back Blows Or Abdominal Thrusts? Getting The First Few Minutes Right</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 03:21:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/beyond-reviewing-ai-output-rebuilding-the-organization-around-new-decisions/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/beyond-reviewing-ai-output-rebuilding-the-organization-around-new-decisions/]]></link>
			<title>Beyond reviewing AI output: Rebuilding the organization around new decisions</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 03:19:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/us-employee-engagement-hits-a-15-year-low-eight-perspectives-for-managers-and-lessons-for-healthcare/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/us-employee-engagement-hits-a-15-year-low-eight-perspectives-for-managers-and-lessons-for-healthcare/]]></link>
			<title>US employee engagement hits a 15-year low: eight perspectives for managers and lessons for healthcare</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 03:13:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/us-risks-losing-measles-elimination-status-after-more-than-5100-cases-in-2026-why-maintaining-the-current-response-may-not-be-enough-to-restore-community-immunity/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/us-risks-losing-measles-elimination-status-after-more-than-5100-cases-in-2026-why-maintaining-the-current-response-may-not-be-enough-to-restore-community-immunity/]]></link>
			<title>US RISKS LOSING MEASLES ELIMINATION STATUS AFTER MORE THAN 5,100 CASES IN 2026: WHY MAINTAINING THE CURRENT RESPONSE MAY NOT BE ENOUGH TO RESTORE COMMUNITY IMMUNITY</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 07:10:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/chinas-drugmakers-turn-to-ai-platforms-to-reach-doctors-could-medical-ai-disrupt-the-traditional-pharmaceutical-sales-model/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/chinas-drugmakers-turn-to-ai-platforms-to-reach-doctors-could-medical-ai-disrupt-the-traditional-pharmaceutical-sales-model/]]></link>
			<title>CHINA&#8217;S DRUGMAKERS TURN TO AI PLATFORMS TO REACH DOCTORS: COULD MEDICAL AI DISRUPT THE TRADITIONAL PHARMACEUTICAL SALES MODEL?</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 07:04:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/aspen-wins-generic-semaglutide-approvals-in-brazil-and-south-africa-can-lower-cost-glp-1-competition-challenge-novo-nordisks-market-advantage/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/aspen-wins-generic-semaglutide-approvals-in-brazil-and-south-africa-can-lower-cost-glp-1-competition-challenge-novo-nordisks-market-advantage/]]></link>
			<title>ASPEN WINS GENERIC SEMAGLUTIDE APPROVALS IN BRAZIL AND SOUTH AFRICA: CAN LOWER-COST GLP-1 COMPETITION CHALLENGE NOVO NORDISK&#8217;S MARKET ADVANTAGE?</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 06:58:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/pfizer-secures-up-to-1-5-billion-from-blackstone-for-obesity-drug-development-why-rd-risk-sharing-could-become-a-new-competitive-advantage-in-glp-1/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/pfizer-secures-up-to-1-5-billion-from-blackstone-for-obesity-drug-development-why-rd-risk-sharing-could-become-a-new-competitive-advantage-in-glp-1/]]></link>
			<title>PFIZER SECURES UP TO $1.5 BILLION FROM BLACKSTONE FOR OBESITY DRUG DEVELOPMENT: WHY R&#038;D RISK-SHARING COULD BECOME A NEW COMPETITIVE ADVANTAGE IN GLP-1</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 06:53:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/phu-quoc-plans-vnd-1-3-trillion-500-bed-hospital-why-infrastructure-expansion-alone-cannot-solve-the-islands-healthcare-capacity-challenge/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/phu-quoc-plans-vnd-1-3-trillion-500-bed-hospital-why-infrastructure-expansion-alone-cannot-solve-the-islands-healthcare-capacity-challenge/]]></link>
			<title>PHU QUOC PLANS VND 1.3 TRILLION, 500-BED HOSPITAL: WHY INFRASTRUCTURE EXPANSION ALONE CANNOT SOLVE THE ISLAND&#8217;S HEALTHCARE CAPACITY CHALLENGE</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 05:48:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/beams-risto-cel-meets-pivotal-sickle-cell-trial-endpoint-can-base-editing-challenge-casgevy-and-lyfgenia-in-the-gene-therapy-market/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/beams-risto-cel-meets-pivotal-sickle-cell-trial-endpoint-can-base-editing-challenge-casgevy-and-lyfgenia-in-the-gene-therapy-market/]]></link>
			<title>BEAM&#8217;S RISTO-CEL MEETS PIVOTAL SICKLE CELL TRIAL ENDPOINT: CAN BASE EDITING CHALLENGE CASGEVY AND LYFGENIA IN THE GENE THERAPY MARKET?</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 06:47:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/bayer-wins-fda-approval-for-sunharbo/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/bayer-wins-fda-approval-for-sunharbo/]]></link>
			<title>BAYER WINS FDA APPROVAL FOR SUNHARBO WITH 26% LOWER RECURRENT STROKE RISK: CAN FIRST-IN-CLASS FACTOR XIa INHIBITION DRIVE GROWTH BEYOND XARELTO?</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 04:03:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://healthcareinsights.vn/]]></guid>
			<link><![CDATA[https://healthcareinsights.vn/]]></link>
			<title>Recent Activity</title>
			<pubDate><![CDATA[Thu, 25 Dec 2025 14:43:05 +0000]]></pubDate>
		</item>
				</channel>
</rss>
